The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1574886310666151014115251 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding the Lymphatic System: Tissue-on-Chip Modeling.
Annu Rev Biomed Eng
January 2025
1Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, North Carolina, USA;
The lymphatic vasculature plays critical roles in maintaining fluid homeostasis, transporting lipid, and facilitating immune surveillance. A growing body of work has identified lymphatic dysfunction as contributing to the severity of myriad diseases and to systemic inflammation, as well as modulating drug responses. Here, we review efforts to reconstruct lymphatic vessels in vitro toward establishing humanized, functional models to advance understanding of lymphatic biology and pathophysiology.
View Article and Find Full Text PDFPlatelet mass index, systemic immune-inflammation index, and neutrophil-lymphocyte ratio as practical markers in childhood brucellosis.
Rev Paul Pediatr
January 2025
Afyonkarahisar Health Sciences University, Faculty of Medicine, Department of Child Health and Diseases, Afyonkarahisar, Turkey.
Objective: Brucellosis is a multisystem infectious disease and may cause an increase in acute phase reactants. This study aimed to examine the platelet mass index (PMI), the neutrophil-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) in children with brucellosis and to determine their roles in focal involvement.
Methods: This retrospective observational study included 69 patients with brucellosis and a control group of 69 healthy children.
Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A cohort study based on the French National Health Data System (SNDS).
PLoS One
January 2025
Pfizer Ltd., Tadworth, United Kingdom.
Background: Risk factors and comorbidities can complicate management of non-valvular atrial fibrillation. We describe and compare real-world safety and effectiveness of direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) and vitamin K antagonists (VKAs) in subgroups of patients with non-valvular atrial fibrillation at high risk for gastrointestinal (GI) bleeding, utilizing data from a national quasi-exhaustive French database.
Methods: Anticoagulant-naïve adults with non-valvular atrial fibrillation with ≥1 gastrointestinal bleeding risk factor, initiating anticoagulant treatment January 2016-December 2019, and covered by the French national health data system were eligible.
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
Eur Thyroid J
January 2025
D Salvatore, Department of Public Health, University of Naples Federico II, Naples, Italy.
Objective: To analyse at our Institution the criteria for selecting a first-line therapy for patients with an advanced radioiodine-refractory thyroid cancer, their clinical responses, safety and survival outcomes.
Patients And Methods: We extracted data from 69 consecutive patients referred from September 2016 to September 2024 at Federico II University Hospital, among whom 44 patients were treated with TKIs as first line treatment and outside any clinical trial, and form the basis of this report.
Results: Thirty-one (71%) patients were treated with the antiangiogenesis inhibitor lenvatinib and 13 (29%) with selective tyrosine kinase inhibitors (s-TKIs).
Clinical course and potential associated factors of progressive calcinosis cutis in early systemic sclerosis: a cohort study.
Ann Med
December 2025
Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Background: Calcinosis cutis of hands can progress and impair hand function in systemic sclerosis (SSc). Understanding the natural disease and comprehensive management is crucial.
Objective: To examine clinical course and identify risk factors associated with progressive calcinosis cutis in early SSc.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!